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Abstract
Background: Little is known about immunovirological treatment outcomes and adherence in HIV/AIDS
patients on antiretroviral therapy (ART) treated using a simplified management approach in rural areas of
developing countries, or about the main factors influencing those outcomes in clinical practice.
Methods: Cross-sectional immunovirological, pharmacological, and adherence outcomes were evaluated
in all patients alive and on fixed-dose ART combinations for 24 months, and in a random sample of those
treated for 12 months. Risk factors for virological failure (>1,000 copies/ml) and subtherapeutic
antiretroviral (ARV) concentrations were investigated with multiple logistic regression.
Results: At 12 and 24 months of ART, 72% (n = 701) and 70% (n = 369) of patients, respectively, were
alive and in care. About 8% and 38% of patients, respectively, were diagnosed with immunological failure;
and 75% and 72% of patients, respectively, had undetectable HIV RNA (<400 copies/ml). Risk factors for
virological failure (>1,000 copies/ml) were poor adherence, tuberculosis diagnosed after ART initiation,
subtherapeutic NNRTI concentrations, general clinical symptoms, and lower weight than at baseline.
About 14% of patients had low ARV plasma concentrations. Digestive symptoms and poor adherence to
ART were risk factors for low ARV plasma concentrations.
Conclusion:  Efforts to improve both access to care and patient management to achieve better
immunological and virological outcomes on ART are necessary to maximize the duration of first-line
therapy.
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Background
In 2007, approximately 810,000 adults were living with
HIV/AIDS in Uganda, and 25–49% of those requiring
antiretroviral therapy (ART) were receiving treatment [1].
Studies conducted in urban areas of Uganda have shown
good therapeutic outcomes in HIV-infected adults treated
with ART [2-7]. However, little is known about immuno-
virological treatment outcomes, likelihood of achieving
therapeutic plasmatic concentrations of antiretroviral
(ARV) drugs, and adherence to treatment of patients
treated using a simplified management approach [8] in
rural areas of developing countries. Also, risk factors for
virological failure have not been extensively investigated.
Rural programs face numerous challenges concerning HIV
care and treatment in Africa, including lack of appropriate
tools to diagnose common opportunistic infections and
qualified human resources. The scale-up of ART in recent
years has not necessarily been accompanied by an
increased strengthening of health systems, and this dispar-
ity is likely to negatively affect the quality of care in HIV/
AIDS programs.
The main objective of this study was to describe clinical
and immunovirological response to ART, patients' self-
reported adherence, and plasma levels of ARV in HIV-
infected adults who received free World Health Organiza-
tion (WHO)-recommended ARV drug regimens as fixed-
dose combinations (FDCs) for 12 or 24 months in Arua,
a rural area in northern Uganda. Furthermore, we investi-
gated potential risk factors for virological failure and for
subtherapeutic concentrations of non-nucleoside reverse
transcriptase inhibitors (NNRTI) or protease inhibitors
(PI).
Methods
Study population
Since 2002, Médecins Sans Frontières (MSF) in collabora-
tion with the Ugandan Ministry of Health has provided
ART free of charge in the regional referral hospital of Arua.
The program initially served the whole West Nile region,
but decentralization of patients on ART to other district
and missionary hospitals was started in 2004. Eligibility
criteria for ART are those recommended in the WHO
guidelines for scaling up ART in resource-poor settings [9].
Patients are seen by nurses monthly or every 3 months for
drug refills and to assess ARV drug toxicity; and by clinical
officers every 2 or 6 months. CD4 T-cell counts are cur-
rently monitored at ART start (for patients with no WHO
clinical stage 4 conditions) and every 6 months (yearly
after the first year on ART since 2005). No routine viral
load (VL) monitoring is performed.
Data routinely collected using standardized forms and
entered into the FUCHIA software (Epicentre, Paris) were,
at program inclusion, date of birth or age, and history of
ARV use; and at ART start, date, regimen, clinical WHO
conditions diagnosed, weight, height, and CD4 T-cell
counts. By November 2005, approximately 8,000 patients
were followed in the program, 90% of them were adults,
and 45% were alive and followed on ART.
Study design
Before the start of the study (November 2005), we identi-
fied patients included in two observational open cohorts
of HIV-infected patients who initiated ART in the previous
12 ± 2 months (M12 cohort) and 24 ± 2 months (M24
cohort). Patients found to be alive and still on ART were
eligible for participation in a cross-sectional survey if they
were contacted within the study window period, were
non-pregnant or breastfeeding at the time of the study,
and provided written informed consent. The study sample
size was calculated assuming that 16% (M12) and 20%
(M24) of these patients, respectively, would have detecta-
ble VL [10,11]. Hence, we included all patients from the
M24 cohort (N = 369) and randomly selected 275
patients from the M12 cohort (N = 701).
Data collection and laboratory testing
During the cross-sectional survey conducted between 28th
November 2005 and 2nd May 2006, we used a standard-
ized questionnaire to collect information on diagnosed
acute severe illnesses, ARV-related toxicity, anthropomet-
ric measurements, and adherence to treatment. Two self-
reported indicators of adherence were calculated: the per-
centage of pills taken in the last 4 days (number of pills
taken as a proportion of the total number of pills pre-
scribed); and the percentage of reported adherence in the
last 30 days using a 6-point visual analogue scale (30-day
VAS). Good adherence was defined as a value ≥ 95% pills
or a VAS score >4 [9].
Plasma concentrations of nevirapine (NVP), efavirenz
(EFV), and nelfinavir (NFV) were determined by high-per-
formance liquid chromatography [12,13] on blood sam-
ples collected 12 hours after ingestion of the last dose of
ARV. Hemoglobin, full blood cell count, alanine ami-
notransferase, and plasmatic creatinine concentrations
were measured. CD4 T-cell counts were quantified using
semi-automated (Cyflow counter, Partec, Münster, Ger-
many) or manual (Dynabead, Dynal Biotech SA,
Compiègne, France) techniques. HIV-1 RNA was quanti-
fied with the ANRS generic real-time PCR test [14]. Geno-
typic resistance tests were performed in plasma samples
with HIV-1 RNA ≥ 1,000 copies/ml using the consensus
technique of the AC11 ANRS 2007 v16; possible resist-
ance was considered as resistance [15,16].
Statistical analysis
Retrospective cohort analysis
Probabilities of survival for all patients included in the
two cohorts were estimated using Kaplan-Meier methods.BMC Infectious Diseases 2009, 9:81 http://www.biomedcentral.com/1471-2334/9/81
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Patients missing their last clinical appointment for 2
months or more were considered lost to follow-up
(LTFU).
Analysis of cross-sectional survey data
Characteristics of patients, ARV toxicity, and adherence
were described using standard statistics. Laboratory ARV
toxicity was graded according to the 2004 AIDS Clinical
Trials Group criteria [17]. We defined immunological fail-
ure as a CD4 T-cell measurement of ≤ 100/mm3 at 12
months, ≤ 200/mm3 at 24 months, or below the value
recorded at ART start at 12 or 24 months of ART [18,19].
Virological failure was defined as the presence of ≥ 1,000
HIV RNA copies/ml. Characteristics of patients at ART
start and at the time of the survey, ARV toxicity, ARV
plasma levels, and adherence were described using stand-
ard statistics.
Based on ARV therapeutic ranges, (4,000–8,000 ng/ml for
NVP, 1,000–4,000 ng/ml for EFV, and 1,000–4,000 ng/ml
for NFV [20]), we defined 3 levels of plasma drug concen-
trations: low (below the lower therapeutic range limit),
normal (within the therapeutic range), and high (above
the higher therapeutic ranged limit).
We investigated predictive factors for virological failure
(HIV-1 RNA ≥ 1,000 copies/ml) and low plasma NVP,
EFV, or NFV concentrations using a multiple logistic
regression analysis. The covariates studied were sex, age
(15–34 vs. ≥ 35 years), level of education (primary or no
education vs. secondary or higher), ARV-experienced,
WHO staging (1/2 vs. 3/4), tuberculosis (TB) diagnosis
after ART initiation, baseline or nadir CD4 cell count (<50
vs. ≥ 50 cells/mm3), weight ≤ baseline, cohort (M12 vs.
M24), presence of ARV-related toxicity, and poor adher-
ence to ART (95% vs. ≥ 95%). For each outcome, we
applied a backwards elimination approach to an initial
model including those covariates associated with the out-
come in univariate analyses (P < 0.25). The goodness-of-
fit χ2 test was used to assess the fit of the final models [21].
All analyses were performed in Stata 9.0 (Stata Corp., Col-
lege Station, TX, USA).
The protocol was approved by the Uganda National
Council for Science and Technology and the Ugandan
AIDS Research Committee.
Results
Retrospective cohort analysis
By the end of the study (May 2006), 130 patients of the
1,523 patients included in the studied cohorts (48/967 of
M12 and 82/556 of M24) had died, and 282 (187 of M12
and 95 of M24) had been lost-to-follow-up. Eighty-three
percent of the 130 recorded deaths occurred during the
first 6 months of ART. Probabilities of survival at 12 and
24 months of ART were 0.91 (95% CI 0.89–0.92) and
0.88 (95% CI 0.86–0.90), respectively, and probabilities
of remaining in care were 0.76 (95% CI 0.74–0.78) and
0.70 (95% CI 0.67–0.72), respectively.
Participants in the cross-sectional survey
Of the 967 adults who initiated ART between September
2004 and July 2005 (M12 cohort), 701 (72%) were still
alive and on ART at the time of the start of the survey. Of
the 556 adults who initiated ART between September
2003 and July 2004 (M24 cohort), 369 (66%) were alive
and on ART. A total of 229 (83% of eligible) M12 and 277
(75% of eligible) M24 patients participated in the cross-
sectional survey. Reasons for exclusion were pregnancy or
breastfeeding, inability to trace the patient, or a screening
visit outside the study period (12 ± 2 or 24 ± 2 months of
ART) (Figure 1). Men and patients ARV-experienced at
ART start were more likely to be included in the study than
women or ARV-naïve patients.
Survey participant characteristics at ART start
Study patients had been followed in the HIV program of
Arua prior to ART initiation for a median time of 6 (M12)
and 4 (M24) months, and 98% were ARV-naïve. At ART
initiation, median age was 37 years, 88% of patients were
in WHO clinical stage 3 or 4, and approximately 17% had
a body mass index (BMI) <17 kg/m2 (Table 1). More than
25% had a CD4 cell count <50 cells/mm3, and most
patients received stavudine/lamivudine/NVP (d4T/3TC/
NVP). Nine percent of patients had been diagnosed with
TB.
Patient characteristics at survey
At the time of the survey, 10 patients were treated for
active TB, and 86% of patients remained on FDC d4T/
3TC/NVP. No patients were receiving second-line therapy.
All participants reported at least one type of clinical intol-
erance, most frequently headache and digestive symp-
toms such as epigastric/abdominal pain or meteorism.
Peripheral polyneuropathy and dermatologic disorders
were reported in more than 30% of patients in both
cohorts. Forty percent of patients had at least one moder-
ate or mild abnormal laboratory result. Seven patients had
grade 3 or 4 abnormal laboratory results, 6 had grade 3
neutropenia (3 M12 and 3 M24), and 1 (M24) grade 4
anemia.
Treatment adherence
In the M12 cohort, good adherence to ART, defined as all
pills taken in the last 4 days, was reported by 200 (87.3%)
patients (or by 198 [86.5%] patients when the 30-day VASBMC Infectious Diseases 2009, 9:81 http://www.biomedcentral.com/1471-2334/9/81
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was used). In the M24 cohort, good adherence to ART in
the last 4 days was reported by 258 (93.1%) patients (250
[90.3%] using VAS) (Table 1).
Overall, the two measures of adherence were moderately
correlated (Pearson's coefficient 0.48) and correlation was
stronger for M12 than for M24 measurements (0.59 and
0.35, respectively). Twenty-seven (6.0%) patients consid-
ered as having good adherence by VAS reported to have
forgotten taking one or more pills in the last 4 days; while
37 (8.1%) of those considered as having good adherence
through 4-day recall reported poor adherence with VAS. A
total of 85 (16.8%) patients were categorized as poorly
adherent to ART by any of the two methods.
Immunological and virological failure
At M12, median CD4 cell count was 223 cell/mm3,
immunological failure was diagnosed in 7.9% of patients,
and 40% had <200 cells/mm3 (Table 1). Furthermore,
75% (171/229) of patients had undetectable HIV RNA
(<400 copies/ml), and 89.1% (204/229) had <1,000 HIV
RNA copies/ml.
At M24, median CD4 cell count was 238 cells/mm3,
immunological failure was diagnosed in 38% of patients,
and 36% of patients had <200 cells/mm3. Seventy-two
percent of patients (198/277) had HIV viral suppression,
and 81.9% (227/277) had <1,000 HIV RNA copies/ml.
Patient cohort profiles at study start (November 2005) Figure 1
Patient cohort profiles at study start (November 2005).
Deaths: 44 (5%)
LTFU: 166 (17%)
ART stopped: 7 (1%)
Transferred: 49 (5%)
Cohort M12
N=967
Alive on ART
N=701 (72%)
Survey participants
N=229
Excluded (n= 46)
Pregnant/ BF =  7
Outside study period =  34 
Other =  2
Not traceable = 3
Screened
N= 275
Deaths: 79 (14%)
LTFU: 90 (16%)
ART stopped: 5 (1%)
Transferred: 13 (2%)
Cohort  M24
N=556
Alive on ART
N= 369 (66%)
Excluded (n=55)
Pregnant/BF = 17
Outside study period = 32 
Other =  2
Not traceable = 4
Screened
N=332
Survey participants
N=277
LTFU, lost to follow-up; ART, antiretroviral therapy; BF, breastfeeding BMC Infectious Diseases 2009, 9:81 http://www.biomedcentral.com/1471-2334/9/81
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Frequency of drug-resistant viruses
We performed genotypic tests for 62 (82.7%) of patients
with VL ≥ 1,000 copies/ml (PCR amplification failed for
13 samples) (Table 2). Five patients (8%) had no muta-
tions. Wild-type viruses were found in 16 (26%; 6 at M12
and 10 at M24) patients. Fourteen (70%) patients at M12
and 32 (76%) at M24 had ≥ 1 mutation conferring drug
resistance to NRTIs or NNRTIs. The overall frequency of
resistant virus among treated patients was 7.3% (14/191)
at M12 and 13.3% (32/240) at M24 (excluding 62
Table 1: Patient characteristics and outcomes
Patient characteristics Cohort M12
(N = 229)
Cohort M24
(N = 277)
Characteristics at ART start
Women (%) 151 (65.9) 173 (62.4)
Median age, years [IQR] 36.8 [32.0–42.3] 36.5 [30.8–42.6]
ARV naïve (%)* 225 (98.2) 273 (98.6)
Median follow-up before ART, months [IQR] 6.2 [3.9–11.4] 3.7 [1.8–7.7]
First ART regimen prescribed d4T/3TC/NVP 226 (98.7) 265 (95.7)
WHO stage 3 or 4 (%) 201 (87.7) 246 (88.8)
Body mass index <17 kg/m2 (%) 38 (17.8); n = 214 43 (16.8); n = 256
CD4 cell count, cells/mm3 n = 133 n = 239
Median [IQR] 100 [45–147] 93 [40–144]
<50 (%) 36 (27.1) 73 (30.5)
Characteristics at time of survey
Non-cumulative WHO stage at survey (%) n = 223 n = 267
Asymptomatic 136 (61.0) 160 (59.9)
Stage 1 or 2 63 (28.2) 86 (32.2)
Stage 3 or 4 24 (10.8) 21 (7.9)
Body mass index, kg/m2
Median [IQR] 20.4 [18.9–22.0] 20.8 [19.0–22.5]
<18.5 kg/m2 (%) 43 (18.8) 52 (18.7)
Median weight gain since ART start, kg [IQR] 3 [1–6] 2 [0–7]
ARV-clinical related symptoms (%)
Asthenia 70 (30.7) 84 (30.3)
Digestive disorders 132 (57.6) 146 (52.7)
Neurological disorders 102 (44.5) 111 (40.1)
Dermatological disorders 70 (30.6) 84 (30.3)
Morphological disorders 39 (17.0) 72 (26.0)
CD4 cell count, cells/mm3
Median [IQR] 223 [163–308] 238 [172–321]
<200 (%) 92 (40.2) 100 (36.1)
Median gain since ART start [IQR] +115 [59–170] +139 [75–215]
Pills taken in last 4 days (%)
Good adherence 200 (87.3) 258 (93.1)
Poor adherence 29 (12.6) 19 (6.9)
30-day VAS (%)
Good adherence 198 (86.5) 250 (90.3)
Poor adherence 31 (13.5) 27 (9.7)
Plasmatic NVP level (%) n = 204 n = 258
Low 39 (19.1) 32 (12.4)
Normal 115 (56.4) 172 (66.7)
High 50 (24.5) 54 (20.9)
Plasmatic EFV level (%) n = 23 n = 18
Low 1 (4.4) -
Normal 13 (56.5) 11 (61.1)
High 9 (39.1) 7 (38.9)
VAS, visual analogue scale; IQR, interquartile range
*ARV-naïve does not include women who received PMTCT prophylaxis.BMC Infectious Diseases 2009, 9:81 http://www.biomedcentral.com/1471-2334/9/81
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patients with VL = 400–999 and 13 with failing amplifica-
tion reaction); or 18.8% (43/229 and 52/277, respec-
tively) if the 75 excluded patients were assumed to have
resistance mutations.
The most prevalent NRTI and NNRTI mutations were
M184V and K103N, respectively. In the M12 cohort, 3
viruses were resistant to EFV and NVP, and 9 to both 3TC
and NNRTIs (EFV and NVP). One virus was resistant to
3TC, d4T, zidovudine (AZT), and NNRTIs (EFV and NVP),
and 1 harbored K65R, K103N, Y181C, and G190A muta-
tions conferring resistance to tenofovir (TDF), EFV, NVP,
and possibly didanosine (ddI).
In the M24 cohort, only 1 virus was resistant to NVP and
EFV, and 22 to both 3TC and NNRTIs. Six viruses with
resistance mutations to both 3TC and NVP had additional
resistance to d4T and/or AZT. Three viruses harbored a
K65R mutation conferring resistance to TDF and possibly
to ddI. One virus had a multidrug resistance profile
(K65R, T69A, V75I, K103N, F116Y, Q151M, V179S,
Y181C, and M184V), conferring resistance to all the
NRTIs and to EFV and NVP.
Thymidine analogue mutations (TAMs) conferring resist-
ance to AZT and d4T were observed in 5% and 14%
patients at M24, respectively. Resistance to both TDF and
ddI were described in 5% (1/20) at M12 and 7% (3/42) at
M24. The NRTI multidrug resistance complex (Q151M)
was found in 1 patient at M24. None of the viruses had
mutations conferring resistance to the new NNRTIs (etra-
virine). Seven patients were resistant to AZT, d4T, 3TC,
NVP, and EFV (6 in M24).
Factors associated with virological failure
Factors significantly associated with virological failure
were longer time on therapy (OR 2.0; 95% CI 1.2–3.6 for
M24 compared with M12 patients), ≥ 35 years of age at
ART start (OR 0.5; 95% CI 0.3–0.8), TB diagnosis during
ART (OR 2.3; 95% CI 1.0–5.0), weight less than baseline
weight at time of ART initiation (OR 2.2; 95% CI 1.3–
3.9), poor adherence (using VAS, OR 3.9; 95% CI 1.9–
7.7), low NNRTI plasma concentration (OR 2.4; 95% CI
1.2–4.8), and presentation of general signs or symptoms
(myalgia, hepatomegaly, splenomegaly, or lymphaden-
opathy; OR 2.6; 95% CI 1.5–4.5) (Table 3).
NNRTI plasma concentrations
In the M12 cohort, plasmatic concentrations of NVP and
EFV were low in 19.1% (39/204) and 4.3% (1/23) of
patients, respectively, and high in 24.5% (50/204) and
39.1% (9/23), respectively. NFV plasmatic concentrations
were within normal therapeutic ranges (n = 2). In the M24
cohort, low plasma NVP concentrations were observed in
12.4% (32/258) of patients and high NVP and EFV con-
centrations in 20.9% (54/258) and 38.9% (7/18), respec-
tively.
Factors associated with low NNRTI plasma concentrations
Overall, the proportion of patients with low ARV concen-
trations significantly increased with increasing HIV RNA
levels (from 12.8% in patients with undetectable VL to
22.7% in those with virological failure, P = 0.02). This
association was observed in both cohorts (Figure 2).
Poor adherence in the last 4 days (OR 3.8, 95% CI 1.9–
7.4) and reported digestive disorders (OR 1.7, 95% CI
0.9–2.9) were significantly associated with the presence of
low plasma NNRTI or NFV concentrations (Table 3), but
these factors were unrelated to the weight of the patients
(data not shown).
Discussion
In the HIV care and treatment program of Arua, in rural
Uganda, more than 70% of the patients remained in care
after 1 or 2 years of treatment, but over 35% of patients
remained at risk of developing opportunistic infections
(<200 cells/mm2). Estimates of retention in care appear to
be more favorable than those reported during the early
years of the Drug Access Initiative (DAI) program among
individuals treated in urban hospitals of Kampala, where
patients were requested to pay the care fees (49–56% at 1
Table 2: Results of virological and genotypic resistance testing by cohort
Cohort M12 Cohort M24
HIV RNA ≥ 1,000 copies/ml (%) 25 50
Available genotypic resistance (%) 20 (80.0) 42 (84.0)
Wild-type virus (%) 6 (30.0) 10 (23.8)
Resistance to ≥ 1 ARV drug (%) 14 (70.0) 32 (76.2)
Resistance to EFV and NVP (%) 3 (15.0) 1 (2.4)
Resistance to 3TC, EFV, and NVP (%) 9 (45.0) 22 (52.4)
Extensive resistance* (%) 2 (10.0) 9 (21.4)
ARV, antiretroviral; EFV, efavirenz; NVP, nevirapine; 3TC, lamivudine
*Resistance to EFV, NVP, 3TC, stavudine, zidovudine, or tenofovir, and didanosine, or multidrug resistance.BMC Infectious Diseases 2009, 9:81 http://www.biomedcentral.com/1471-2334/9/81
Page 7 of 11
(page number not for citation purposes)
year, and 46% at 2 years of ART) and more than 30% were
ARV-experienced [3,5]. Like in other African settings, most
of our patients started treatment at an advanced stage of
HIV disease [4,10,22-24], which partly explains why a
considerable proportion of patients had low CD4 cell
counts after 1 or 2 years of therapy. As reported previously
[11,25-27], early mortality in our cohorts was high with
88% of deaths occurring in the first 6 months of follow-
up under ART. Delays in access to care (>80% of patients
started treatment at an advanced clinical stage of HIV dis-
ease), delayed diagnosis and treatment of severe oppor-
tunistic infections (e.g. TB), undiagnosed severe immune
reconstitution inflammatory syndromes, and nutritional
deficiencies might have contributed to this increased early
mortality [28-31].
Despite the frequency of clinical intolerances reported,
the initial ART regimen was well tolerated, and few cases
Table 3: Factors associated with virological failure and low plasma NNRTI concentrations
Virological failure Low NNRTI concentrations
n/N Univariate analysis Multivariate analysis† n/N Univariate analysis Multivariate analysis†
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
M24 cohort 
(vs. M12)
50/506 1.8 (1.1–3.0) 0.02 2.0 (1.2–3.6) 0.01 32/505 0.6 (0.4–1.0) 0.06 0.7 (0.4–1.1) 0.15
Age at ART 
start (vs. 15–34)
≥ 35 years 40/506 0.5 (0.3–0.9) 0.02 0.5 (0.3–0.8) 0.01 46/505 1.1 (0.7–1.9) 0.58 - -
School level (vs. secondary or higher)
Primary or no 
education
47/506 0.8 (0.5–1.4) 0.50 - - 53/505 1.5 (0.9–2.6) 0.14 1.3 (0.8–2.4) 0.3
Non-cumulative WHO stage at survey (vs. asymptomatic)
Stage 1–2 32/490 1.9 (1.2–3.3) 0.04 1.9 (1.1–3.3) 0.06
S t a g e  3 – 4 6 / 4 9 0 1 . 1  ( 0 . 4 – 2 . 8 ) 0 . 8  ( 0 . 3 – 2 . 2 ) - ----
TB episode after 
ART
1 1 / 5 0 6 2 . 1  ( 0 . 9 – 4 . 3 ) 0 . 0 6 2 . 3  ( 1 . 0 – 5 . 0 ) 0 . 0 4 - ----
Weight ≤ baseline 32/506 1.9 (1.2–3.3) 0.009 2.2 (1.3–3.9) 0.004 15/505 0.6 (0.3–1.1) 0.07 0.6 (0.3–1.1) 0.11
ARV-related 
toxicity
Digestive 49/506 1.6 (0.9–2.8) 0.05 1.5 (0.8–2.6) 0.15 48/505 1.8 (1.1–3.0) 0.03 1.7 (0.9–2.9) 0.05
Dermatologic 31/506 1.8 (1.1–2.9) 0.03 1.6 (0.9–2.8) 0.08 21/505 0.9 (0.5–1.6) 0.82 - -
General 
symptoms*
30/506 2.3 (1.4–3.9) 0.002 2.6 (1.5–4.5) 0.001 17/505 0.9 (0.5–1.6) 0.74 - -
Poor adherence to ART (<95% vs. ≥ 95%)
% pills taken in 
last 4d
11/506 1.8 (0.0–3.8) 0.11 1.1 (0.4–2.6) 0.85 17/505 4.0 (2.1–7.7) 0.0001 3.8 (1.9–7.4) <0.0001
3 0 - d a y  V A S 1 9 / 5 0 6 3 . 4  ( 1 . 8 – 6 . 4 ) 0 . 0 0 0 2 3 . 9  ( 1 . 9 – 7 . 7 ) 0 . 0 0 0 1 - ----
Nadir CD4+ <50 
cells/mm3 (vs. ≥ 
50)
24/506 1.5 (0.9–2.6) 0.14 1.5 (0.8–2.6) 0.20 19/503 1.1 (0.6–1.9) 0.77 - -
Low NNRTI 
plasma 
concentration at 
survey
1 7 / 5 0 5 1 . 9  ( 1 . 1 – 3 . 7 ) 0 . 0 3 2 . 4  ( 1 . 2 – 4 . 8 ) 0 . 0 1 - ----
TB, tuberculosis; VAS, visual analogue scale; NNRTI, non-nucleoside reverse transcriptase inhibitor; OR, odds ratio; CI, confidence interval.
*General signs or symptoms: myalgia, hepatomegaly, splenomegaly, or lymphadenopathy; VAS.
†Multiple logistic regression using backward elimination approach and controlling for the effect of all variables for which adjusted estimates are 
shown.BMC Infectious Diseases 2009, 9:81 http://www.biomedcentral.com/1471-2334/9/81
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of severe (grades 3 or 4) laboratory-based toxicity were
diagnosed. Self-reported adherence at 12 and 24 months
of ART was high and similar to that reported in other stud-
ies, both in resource-limited countries [32] and North
America [33,34], with a higher proportion of patients
reporting good adherence in the M24 cohort than the
M12 cohort (90% compared with 80%, respectively).
Although reported adherence is subject to measurement
error and we cannot exclude that some patients over-
reported their level of adherence to ART during the survey,
these findings were consistent with plasmatic ARV phar-
macological measurements obtained in the same patients.
However, the reported levels of adherence do not neces-
sarily reflect patient's compliance throughout the dura-
tion of treatment.
The observed immune and virological responses at 1 and
2 years of ART were similar to those reported in other Afri-
can settings [4,10,11,22,35,36] and in Western countries
[37]. However, more than 35% of patients had a CD4
count <200 cells/ml and were therefore at increased risk of
death due to occurrence of opportunistic diseases. In the
M12 cohort, undetectable VL was achieved by 75% of the
patients, and 89% had a VL <1,000 copies/ml. In Malawi,
87% of the patients receiving a 2 NRTI/1 NNRTI-based
regimen had a VL <1,000 copies/ml after a median of 10
months [10]. The DART study conducted in Zimbabwe
and Uganda reported that 72% of patients who received
AZT/3TC/TDF for a year had undetectable VL [4]. Also, in
a teaching hospital of Kampala, undetectable VL was
observed in 86% of patients treated with d4T/3TC/NVP
for 1 year [7]. Similarly, in a patient cohort in Khayelitsha,
South Africa, 70% of patients achieved undetectable VL at
1 year of ART [11]. In our M24 cohort, undetectable VL
was achieved by 71% of the patients. Lower virological
success rates have been reported in four urban clinics in
Senegal, Côte d'Ivoire, Uganda, and Kenya after 2 years of
ART (40–69% had a VL <400 copies/ml) [36].
Overall, 7% of patients with virological failure at M12 and
13% at M24 had resistant virus, which is similar to esti-
mates reported for patients treated with 2 NRTI/1 NNRTI-
based therapy in east Africa or South-east Asia after more
than 9 months of treatment (9–18%) [10,35,38]. This fig-
ure might be underestimated if patients with unsup-
pressed HIV VL (400–999 copies/ml) but not virological
failure also had viral mutations conferring resistance to
therapy. More conservative estimates of prevalence of
resistance would therefore be 18% and 21% of M12 and
M24 patients, respectively, on treatment.
HIV-1 RNA values by ARV drug plasma level and by cohort Figure 2
HIV-1 RNA values by ARV drug plasma level and by cohort.
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Estimates of resistance and virological and immunologi-
cal failure might also have been underestimated if some of
the deaths or patients who were lost to follow-up died as
a result of treatment failure and resistance. However, most
deaths and losses to follow-up occurred within the first
months of therapy when the likelihood of treatment fail-
ure was lower. Conversely, because our study is based on
outcome data collected at a single time point and no con-
firmation of laboratory data was obtained in the follow-
ing weeks, we might have slightly overestimated rates of
virological and immunological failure due to measure-
ment errors or to individual temporal variability in bio-
logical markers (e.g. HIV viral blips). As in previous
studies conducted in patients using primarily d4T/3TC/
NVP, the most commonly observed resistance mutations
were those associated with the use of NNRTIs (K103N)
and 3TC (M184V) [7,10,38], and none of the isolated
viruses had mutations conferring resistance to the new
NNRTIs (etravirine).
Patients on ART for 2 years were twice as likely as those on
1 year treatment to develop virological failure. Patients
diagnosed with TB after ART initiation were also more
likely to fail therapy, suggesting that patients' virological
response could be impaired when rifampicin-based anti-
TB treatment is initiated while a patient is under ART. The
potential interaction between NVP and rifampicin in HIV-
infected patients treated for TB has been reported in previ-
ous studies [39-43]. This can result in subtherapeutic NVP
plasma concentrations [39] and favor the development of
resistance to this drug. Alternatively, pill burden associ-
ated with concomitant treatments could lead to decreased
adherence to one or both regimens.
Early identification of patients with virological failure and
switch to second-line therapy is important to prevent the
accumulation of resistance that might compromise the
effectiveness of subsequent lines of treatment. In this pro-
gram where virological monitoring of patients is not rou-
tinely performed, patients presenting general clinical
symptoms, those with a weight loss below the value
observed at therapy initiation, or those reporting poor
adherence were more likely to have virological failure. The
association between high VL levels and subtherapeutic
NNRTI concentrations has been previously reported in
Malawi [44] and Cambodia [38], highlighting the impor-
tance of maintaining and reinforcing patients' adherence
over time. In our study, patients severely immunosup-
pressed at the time of the survey were not more likely to
have virological failure, although this might change if
patients remain in a failing regimen for longer periods of
time [38].
The pharmacological assessment showed increased plas-
matic levels of NNRTI in 23% of patients on NVP-based
therapy and 39% of those on EFV. These figures are higher
than what has been described in Western countries, and
are likely to be related to the lower weight of our patients
at ART initiation [44] compared with European patients
[45,46]. In contrast, subtherapeutic levels of NVP and EFV
were found in 15% and 2% of the patients, respectively.
As in previous studies, the risk of having low NNRTI con-
centrations in plasma was nearly 4 times higher in
patients with poor self-reported adherence [44,47]. We
also found a higher risk of subtherapeutic ARV levels in
patients who reported digestive disorders at the time of
the survey. Vomiting, malabsorption, or misclassification
bias (e.g. if patients who reported symptoms were also
more likely to report poor adherence) could contribute to
explain this finding.
Conclusion
In conclusion, in this HIV/AIDS care program imple-
mented in a rural African setting using a simplified scale-
up approach and free generic ART, survival and retention
in care were satisfactory at up to 2 years of therapy, but
efforts to increase earlier access to treatment and to
improve patient management and support to achieve bet-
ter immunological and virological outcomes on ART
remain necessary to prolong patient survival. Early identi-
fication of poor adherence during follow-up, especially in
the presence of intolerance to ARV and when TB treatment
is provided, should be considered to maximize the dura-
tion of first-line therapy.
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